Ravulizumab is eculizumab, Carsten. They work the same way. It is the same monoclonal antibody. It has just been modified in a couple of places so that it is effective…
When Jeff, the producer of these awareness day videos, suggested that "questions" should be the theme of this years' RDD Video I was surprised. Surprised because it had been five…
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a controlled trial of patients selected to test withdrawal of…
People with atypical HUS need urgent care during periods of disease activity, with treatment when needed for as long as needed. But how is such optimal care duration determined, and…
Atypical HUS Research – What’s New? The aHUS Alliance Global Action team has created a virtual ‘library’ of publications that are aHUS-specific and are categorized by topics such as diagnosis, treatment, genetics, thrombotic microangiopathy (TMA), complement, transplant, pregnancy, and more.
Article No. 442 23 June 2021 Today NICE ( The National Institute for Health and Care Excellence) concluded its evaluation of ravulizumab for treating aHUS by publishing its Final Guidance…
Article No 441 18 June 2021 What topics and questions are likely to frame conversations about treating patients who have atypical HUS? Since aHUS diagnosis begins with ruling…
Article No. 419 16 February 2021 It is spring time in 2017. You feel very unwell, very poorly. It is thought you have aHUS. You get a chance to have…